Drug Research

Despite the fact that the decision to severely restrict coverage of an expensive new Alzheimer's medicine, U.S. President Joe Biden celebrated success on September 27th by claiming that expenditures for tens of millions of Americans enrolled in the Medicare...

In order to ultimately enhance the outcomes and care for children and people with chronic conditions, especially as novel variants emerge, the Australian government is funding a new study on COVID-19 vaccinations and infection. The new PROPHECY study, directed by...

The Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership created to advance the development of treatments for amyotrophic lateral sclerosis (ALS) and similar rare neurodegenerative conditions, has been initiated by the US Food and Drug Administration...

A quarter of patients with a variety of advanced tumours have shown signals of benefit from RP2, a modified form of the herpes simplex virus, according to research. The trial's participants had malignancies of the head and neck, oesophagus,...

The fixed-dose combination Opdualag (nivolumab and relatlimab) from Bristol Myers Squibb (BMS) has received clearance from the European Commission for use as the first-line therapy for advanced unresectable or metastatic melanoma. Patients aged 12 years and older who have cancer...

Within one firm, the title of most costly treatment in the world has changed hands within a month. Bluebird Bio has received an FDA fast clearance for Skysona, also known as eli-cel, for the uncommon neurological condition cerebral adrenoleukodystrophy (CALD),...

QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. According to the terms...